Contact Us
Drug Search Results
More Filters [+]

Filorexant

Alternative Names: filorexant, mk-6096
Latest Update: 2023-07-26
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: OX1R Antagonist,OX2R

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Filorexant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Insomnia|Pain Unspecified|Depressive Disorder, Major|Depressive Disorder|Migraine Disorders|Headache Disorders

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MK-6096-022

P2

Terminated

Depressive Disorder, Major

2013-09-03

2011-005200-15

P2

Completed

Depressive Disorder

2013-09-03

MK-6096-021

P2

Completed

Pain Unspecified

2013-04-18

MK-6096-020

P2

Completed

Migraine Disorders|Headache Disorders

2012-10-03

Recent News Events

Date

Type

Title

07/26/2023

PubMed

 Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia.

06/19/2023

PubMed

 Orexin Receptor Antagonists as Adjunct Drugs for the Treatment of Depression: A Mini Meta-Analysis.

02/05/2023

PubMed

 Dual orexin/hypocretin receptor antagonism attenuates attentional impairments in an NMDA receptor hypofunction model of schizophrenia.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions